dual agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual inspection serves only as a preliminary check |
| Solubility | Freely soluble in water and aqueous buffers | Gentle mixing may be needed to reach full dissolution |
| Typical storage | Minus 20 degrees Celsius or colder, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Primary analytical method | Reversed-phase HPLC with mass detection | Purity reported as chromatographic area percent |
| Common synonyms | GIP/GLP-1 dual agonist; LY3298176 | Development codes are distinct from approved product names |
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Mutations in kinases that lead to a loss-of-function or gain-of-function can cause cancer and disease in humans, including certain types of leukemia and neuroblastomas, glioblastoma, spinocerebellar ataxia (type 14), forms of agammaglobulinaemia, and many others.
Mark Stoyer, a nuclear chemist at the LLNL, later recalled, "We had intended to propose that name from Livermore, and things kind of got proposed at the same time from multiple places. I don't know if we can claim that we actually proposed the name, but we had intended it." In internal discussions, IUPAC asked the JINR if they wanted the element to be spelled "oganeson" to match the Russian spelling more closely. Oganessian and the JINR refused this offer, citing the Soviet-era practice of transliterating names into the Latin alphabet under the rules of the French language ("Oganessian" is such a transliteration) and arguing that "oganesson" would be easier to link to the person. In June 2016, IUPAC announced that the discoverers planned to give the element the name oganesson (symbol: Og). The name became official on 28 November 2016. In 2017, Oganessian commented on the naming:
==== Recombinant DNA ==== Biotechnology in the modern sense of genetic engineering began in the 1970s, with the invention of recombinant DNA techniques. Restriction enzymes were discovered and characterized in the late 1960s, following on the heels of the isolation, then duplication, then synthesis of viral genes. Beginning with the lab of Paul Berg in 1972 (aided by EcoRI from Herbert Boyer's lab, building on work with ligase by Arthur Kornberg's lab), molecular biologists put these pieces together to produce the first transgenic organisms. Soon after, others began using plasmid vectors and adding genes for antibiotic resistance, greatly increasing the reach of the recombinant techniques. Wary of the potential dangers (particularly the possibility of a prolific bacteria with a viral cancer-causing gene), the scientific community as well as a wide range of scientific outsiders reacted to these developments with both enthusiasm and fearful restraint. Prominent molecular biologists led by Berg suggested a temporary moratorium on recombinant DNA research until the dangers could be assessed and policies could be created. This moratorium was largely respected, until the participants in the 1975 Asilomar Conference on Recombinant DNA created policy recommendations and concluded that the technology could be used safely. Following Asilomar, new genetic engineering techniques and applications developed rapidly. DNA sequencing methods improved greatly (pioneered by Frederick Sanger and Walter Gilbert), as did oligonucleotide synthesis and transfection techniques.
=== Hemoglobin synthesis and function === PLP aids in the synthesis of hemoglobin, by serving as a coenzyme for the enzyme aminolevulinic acid synthase. It also binds to two sites on hemoglobin to enhance the oxygen binding of hemoglobin.
XCMS Online is a cloud version of the original eXtensible Computational Mass Spectrometry (XCMS) technology (a bioinformatics software designed for statistical analysis of mass spectrometry data), created by the Siuzdak Lab at Scripps Research. XCMS introduced the concept of nonlinear retention time alignment that allowed for the statistical assessment of the detected peaks across LCMS and GCMS datasets. XCMS Online was designed to facilitate XCMS analyses through a cloud portal and as a more straightforward (non command driven) way to analyze, visualize and share untargeted metabolomic data. Further to this, the combination of XCMS and METLIN with 960,000 authentic standards, allows for the identification of known molecules using METLIN's tandem mass spectrometry data, and enables the identification of unknown (uncharacterized molecules) via similarity searching of tandem mass spectrometry data. XCMS Online has also become a systems biology tool for integrating different omic data sets. As of January 2021, the XCMSOnline - METLIN platform has over 44,000 registered users. XCMS - METLIN was recognized in 2023 as the year's top analytical innovation. XCMS Online works by comparing groups of raw or preprocessed metabolomic data to discover metabolites using methods such as nonlinear retention time alignment and feature detection & matching. Once analysis is complete the data can be viewed several different ways including via bubble plots, heat maps, chromatograms, and box plots. In addition, XCMS Online is integrated with METLIN, a large metabolite database.
Sources: en.wikipedia.org
American Ornithologists’ Union Committee on Bird Collections ORNithological Information System (ORNIS) Type-specimens in 3D Extinct specimens in 3D (National History Museum of the Netherlands — Naturalis) Museum handbook Inventory of major European bird collections F.D. Steinheimer The whereabouts of pre-nineteenth century bird specimens Zool. Med. Leiden 79-3 (5), 30-ix-2005, 45-67.— ISSN 0024-0672. ebeac electronic index of bird collections
Sulfasalazine: Sulfapyridine linked via an azo group to 5-aminosalicylic acid. Alpha-GPC: Choline linked to glycerophosphate. Benorylate: Paracetamol linked via esterification to acetylsalicylic acid. Cod-THC: THC linked via a carbonate group to codeine. Fenethylline: Amphetamine linked to theophylline. Sultamicillin: ampicillin linked via esterification to sulbactam. Cefilavancin: a vancomycin derived antibiotic linked to a cephalosporin antibiotic. Rifaquizinone: a rifamycin derived antibiotic linked to a quinolone antibiotic. Proglumetacin: indometacin linked to proglumide Dimenhydrinate: Diphenhydramine formed into a salt with 8-chlorotheophylline
The Tissue resource of the Human Protein Atlas focuses on the expression profiles in human tissues of genes both on the mRNA and protein level. The protein expression data from 45 normal human tissue types is derived from antibody-based protein profiling using conventional and multiplex immunohistochemistry. All underlying images of immunohistochemistry stained normal tissues are available together with knowledge-based annotation of protein expression levels. The Brain section provides comprehensive spatial profiling of the brain, including overview of protein expression in the mammalian brain based on integration of data from human, pig and mouse. Transcriptomics data combined with affinity-based protein in situ localization down to single cell detail is available in this brain-centric sub atlas of the Human Protein Atlas. The data presented are for human genes and their one-to-one orthologues in pig and mouse. Gene summary pages provide the hierarchical expression landscape form 13 main regions of the brain to individual nuclei and subfields for every protein coding gene. For selected proteins, high content images are available to explore the cellular and subcellular protein distribution. In addition, the Brain section contains lists of genes with elevated expression in one or a group of regions to help the user identify unique protein expression profiles linked to physiology and function.
Pelvic floor muscles help to support the vulvar structures. The voluntary, pubococcygeus muscle, part of the levator ani muscle partially constricts the vaginal opening. Other muscles of the urogenital triangle support the vulvar area and they include the transverse perineal muscles, the bulbospongiosus, and the ischiocavernosus muscles. The bulbospongiosus muscle decreases the vaginal opening. They play a role in the vaginal contractions of orgasm by causing the vestibular bulbs to contract.
=== Disorders of mineral metabolism === 275 Disorders of mineral metabolism 275.0 Disorders of iron metabolism Aceruloplasminemia Hemochromatosis 275.1 Disorders of copper metabolism Wilson's disease 275.2 Disorders of magnesium metabolism Hypermagnesemia Hypomagnesemia 275.3 Disorders of phosphorus metabolism Familial hypophosphatemia Hypophosphatasia 275.4 Disorders of calcium metabolism 275.41 Hypocalcemia 275.42 Hypercalcemia 275.49 Pseudohypoparathyroidism
Sources: en.wikipedia.org
The Drug Prevention Network of Canada states that harm reduction has "...come to represent a philosophy in which illicit substance use is seen as largely unpreventable, and increasingly, as a feasible and acceptable lifestyle as long as use is not 'problematic'", an approach which can increase "acceptance of drug use into the mainstream of society". They say harm reduction "...sends the wrong message to ... children and youth" about drug use. In 2008, the Declaration of World Forum Against Drugs criticized harm reduction policies that "...accept drug use and do not help drug users to become free from drug abuse", which the group say undermines "...efforts to limit the supply of and demand for drugs." They state that harm reduction should not lead to less efforts to reduce drug demand. Pope Benedict XVI criticised harm reduction policies with regards to HIV/AIDS, saying that it was "a tragedy that cannot be overcome by money alone, that cannot be overcome through the distribution of condoms, which even aggravates the problems". This position was in turn widely criticised for misrepresenting and oversimplifying the role of condoms in preventing infections. A March 2025 study exploring the association of safer supply and decriminalization policy with opioid overdose outcomes in British Columbia, Canada, found that neither policy "appeared to mitigate the opioid crisis, and both were associated with an increase in opioid overdose hospitalizations."
Tanners usually contain a sunscreen. However, when avobenzone is irradiated with UVA light, it generates a triplet excited state in the keto form which can either cause the avobenzone to degrade or transfer energy to biological targets and cause deleterious effects. It has been shown to degrade significantly in light, resulting in less protection over time. The UV-A light in a day of sunlight in a temperate climate is sufficient to break down most of the compound. It's important to continue wearing SPF while self-tanning, as self-tanner is generally a fake and temporary tan, and your skin is still sensitive to the sun. If avobenzone-containing sunscreen is applied on top of tanner, the photosensitizer effect magnifies the free-radical damage promoted by DHA, as DHA may make the skin especially susceptible to free-radical damage from sunlight, according to a 2007 study led by Katinka Jung of the Gematria Test Lab in Berlin. Forty minutes after the researchers treated skin samples with 20% DHA they found that more than 180 percent additional free radicals formed during sun exposure compared with untreated skin. A toxicologist and lung specialist at the University of Pennsylvania's Perelman School of Medicine (Dr. Rey Panettieri) has commented, "The reason I'm concerned is the deposition of the tanning agents into the lungs could really facilitate or aid systemic absorption -- that is, getting into the bloodstream.
The molybdenum for steel production is reduced by the aluminothermic reaction with the addition of iron to produce ferromolybdenum. A common form of ferromolybdenum contains 60% molybdenum. Molybdenum was valued at approximately $30,000 per tonne as of August 2009. It maintained a price at or near $10,000 per tonne from 1997 through 2003, and reached a peak of $103,000 per tonne in June 2005. In 2008, the London Metal Exchange announced that molybdenum would be traded as a commodity.
=== 11 December === Ukrainian President Volodymyr Zelenskyy said that Russian forces have turned the city of Bakhmut into "burned ruins". The Ukrainians killed up to 60 and injured nearly 100 Russian soldiers near Kadiivka, Luhansk Oblast. They also killed 150 Russian soldiers and destroyed 10 pieces of equipment during strikes in Zaporizhzhia Oblast.
== External links == Fisher HealthCare Clinical Catalog - The Digital Edition Fisher HealthCare Rapid Diagnostics Catalog - The Digital Edition 1980 article on Fisher's product line ISO 9001:2015 Quality System Certified Organization, Scientific Lab Equipment 1987 article on Fisher products
Sources: en.wikipedia.org
Liquid chromatography combined with mass spectrometry is the most common approach. Digestion followed by peptide mapping verifies the sequence and modification sites. Results are judged against a reference standard or a theoretically calculated mass.
Lower temperatures slow most degradation routes, and storage at minus twenty degrees Celsius or below is standard for lyophilized material. Repeated warming and cooling imposes stress on the molecule. Dissolved samples deteriorate faster and are usually handled over shorter periods.
It normally reflects the relative chromatographic area of the principal peak. It does not capture every possible impurity or demonstrate biological function. Additional methods are required to describe a sample completely.
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.